Arcus BiosciencesRCUS
RCUS
About: Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Employees: 674
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
144% more call options, than puts
Call options by funds: $5.08M | Put options by funds: $2.08M
53% more capital invested
Capital invested by funds: $814M [Q3] → $1.25B (+$435M) [Q4]
33.45% more ownership
Funds ownership: 58.24% [Q3] → 91.68% (+33.45%) [Q4]
8% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 24
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
1% less funds holding
Funds holding: 185 [Q3] → 184 (-1) [Q4]
8% less repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 66
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$14
60%
upside
Avg. target
$20
129%
upside
High target
$25
186%
upside
4 analyst ratings
3 positive
75%
1 neutral
25%
0 negative
0%
Barclays Peter Lawson 14% 1-year accuracy 3 / 22 met price target | 60%upside $14 | Overweight Maintained | 23 Apr 2025 |
HC Wainwright & Co. Emily Bodnar 21% 1-year accuracy 33 / 160 met price target | 174%upside $24 | Buy Upgraded | 26 Feb 2025 |
B of A Securities Jason Zemansky 50% 1-year accuracy 5 / 10 met price target | 94%upside $17 | Neutral Maintained | 19 Feb 2025 |
Morgan Stanley Terence Flynn 50% 1-year accuracy 11 / 22 met price target | 186%upside $25 | Overweight Maintained | 18 Feb 2025 |
Financial journalist opinion
Based on 5 articles about RCUS published over the past 30 days
Neutral
Business Wire
6 days ago
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 39,750 shares of the Company's common stock at an exercise price per share of $8.11, which was the closing price on April 23, 2025 and re.
Neutral
Business Wire
1 week ago
Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that data from the ARC-20 study will be presented in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30 – June 3, 2025. The oral presentation will highlight the first safety and efficacy data for the ARC-20.
Neutral
Business Wire
1 week ago
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will host a conference call and webcast on Tuesday, May 6th, 2025 at 1:30 PM PT / 4:30 PM ET to discuss details of the Company's financial results and pipeline update for the quarter ended March 31st, 2025. Investors interested in listening to the c.
Neutral
Business Wire
3 weeks ago
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted six new employees options to purchase a total of 16,960 shares of the Company's common stock at an exercise price per share of $7.04, which was the closing price on April 8, 2025, and re.
Positive
Seeking Alpha
4 weeks ago
Arcus Biosciences: A High-Risk Speculation With Multiple Large, Near-Term Catalysts
Arcus Biosciences presents a high-risk speculation with significant upcoming catalysts, despite recent stock declines and Gilead's exit from the ARC-10 trial. Gilead's continued investment and board presence indicate confidence in Arcus, despite the challenges faced with domvanalimab. Arcus has a diverse pipeline targeting pancreatic and renal cell carcinoma, with promising Phase 3 trials that could significantly boost the stock.
Neutral
Business Wire
1 month ago
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted twelve new employees options to purchase a total of 42,920 shares of the Company's common stock at an exercise price per share of $9.12, which was the closing price on March 24, 2025, an.
Neutral
Business Wire
2 months ago
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in March: Leerink Global Healthcare Conference 2025 Date: Wednesday, March 12th, 2025 Location: Miami Beach, FL Format: Fireside chat & 1x1 meetings Time: 8:00 a.m. ET Barclays 27th.
Negative
Zacks Investment Research
2 months ago
Arcus Biosciences, Inc. (RCUS) Reports Q4 Loss, Tops Revenue Estimates
Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $1.17. This compares to loss of $1.08 per share a year ago.
Neutral
Business Wire
2 months ago
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a pipeline update on its clinical-stage investigational molecules across multiple common cancers. “Last week, we presented data from nearly 90 ccRCC patients demonstratin.
Neutral
Business Wire
2 months ago
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted one new employee options to purchase a total of 5,550 shares of the Company's common stock at an exercise price per share of $11.07, which was the closing price on February 21, 2025, and.
Charts implemented using Lightweight Charts™